Published in J Neuropsychiatry Clin Neurosci on January 01, 2013
Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder. Mol Psychiatry (2014) 0.83
Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder. Dialogues Clin Neurosci (2014) 0.80
Current source density analysis of resting state EEG in depression: a review. J Neural Transm (Vienna) (2015) 0.79
Predicting cognitive behavioral therapy response in social anxiety disorder with anterior cingulate cortex and amygdala during emotion regulation. Neuroimage Clin (2017) 0.75
Recent advances in predicting responses to antidepressant treatment. F1000Res (2017) 0.75
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry (2011) 3.34
Randomized controlled trial of trigeminal nerve stimulation for drug-resistant epilepsy. Neurology (2013) 2.62
Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry (2002) 2.39
Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety (2012) 2.23
Yoga as a complementary treatment of depression: effects of traits and moods on treatment outcome. Evid Based Complement Alternat Med (2007) 2.22
Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry (2005) 1.99
American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry (2007) 1.79
Growth modeling with nonignorable dropout: alternative analyses of the STAR*D antidepressant trial. Psychol Methods (2011) 1.49
A web-based data management system to improve care for depression in a multicenter clinical trial. Psychiatr Serv (2002) 1.48
Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psychiatry (2004) 1.42
Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res (2009) 1.40
Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol (2010) 1.29
Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res (2009) 1.18
Biomarkers to predict antidepressant response. Curr Psychiatry Rep (2010) 1.14
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry (2007) 1.14
Trigeminal nerve stimulation in major depressive disorder: first proof of concept in an open pilot trial. Epilepsy Behav (2011) 1.11
fMRI activation in the amygdala and the orbitofrontal cortex in unmedicated subjects with major depressive disorder. Psychiatry Res (2010) 1.10
Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. J Psychiatr Res (2009) 1.09
A role for profiles of patient-specific depression characteristics and socioeconomic factors in the prediction of antidepressant treatment outcome. J Clin Psychiatry (2015) 1.07
Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology (2002) 1.06
Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J Psychiatr Res (2005) 1.05
Longitudinal progression of subclinical structural brain disease in normal aging. Am J Geriatr Psychiatry (2004) 1.04
Trigeminal nerve stimulation: seminal animal and human studies for epilepsy and depression. Neurosurg Clin N Am (2011) 1.04
Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. Clin Neurophysiol (2004) 1.03
Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study. Epilepsy Behav (2013) 1.02
Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol (2009) 1.01
Functional neuroanatomy of visual masking deficits in schizophrenia. Arch Gen Psychiatry (2009) 0.99
Cognitive and physiologic correlates of subclinical structural brain disease in elderly healthy control subjects. Arch Neurol (2002) 0.98
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry (2006) 0.96
White matter injury, neural connectivity and the pathophysiology of psychiatric disorders. Dev Neurosci (2002) 0.93
Treatment of patients with substance use disorders, second edition. American Psychiatic Association. Am J Psychiatry (2006) 0.93
A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci (2009) 0.93
Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology (Berl) (2004) 0.93
Characteristics of insured and noninsured outpatients with depression in STAR(*)D. Psychiatr Serv (2005) 0.93
Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clin Neurophysiol (2003) 0.92
The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder. Front Hum Neurosci (2013) 0.92
Midline and right frontal brain function as a physiologic biomarker of remission in major depression. Psychiatry Res (2009) 0.92
A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res (2013) 0.90
Predictive socioeconomic and clinical profiles of antidepressant response and remission. Depress Anxiety (2013) 0.90
Does the clinical course of depression determine improvement in symptoms and quality of life? J Nerv Ment Dis (2006) 0.89
Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression. Clin Neurophysiol (2009) 0.89
Brain electrical source differences between depressed subjects and healthy controls. Brain Topogr (2008) 0.89
Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry (2005) 0.87
Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depression. PLoS One (2012) 0.87
Relationship between medical student perceptions of mistreatment and mistreatment sensitivity. Med Teach (2012) 0.86
Baroreflex mechanisms in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.86
A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. J Clin Psychiatry (2014) 0.86
The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. Psychiatr Clin North Am (2007) 0.86
Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics (2005) 0.85
Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. J Clin Psychopharmacol (2010) 0.85
Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav (2013) 0.85
Aging and brain activation with working memory tasks: an fMRI study of connectivity. Int J Geriatr Psychiatry (2007) 0.84
Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder. Psychiatry Res (2011) 0.82
Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder. Psychopharmacology (Berl) (2015) 0.81
Changes in brain function during administration of venlafaxine or placebo to normal subjects. Clin EEG Neurosci (2008) 0.81
Quantitative EEG abnormalities are associated with memory impairment in recently abstinent methamphetamine-dependent individuals. J Neuropsychiatry Clin Neurosci (2009) 0.80
Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology (2005) 0.80
Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments. Ann N Y Acad Sci (2015) 0.80
Neuromodulation for depression: invasive and noninvasive (deep brain stimulation, transcranial magnetic stimulation, trigeminal nerve stimulation). Neurosurg Clin N Am (2014) 0.80
Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression. J Clin Psychopharmacol (2010) 0.79
Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: a pilot study. Int J Geriatr Psychiatry (2002) 0.79
Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial. J Clin Psychiatry (2013) 0.79
Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study. Psychooncology (2014) 0.79
Neurophysiologic changes during estrogen augmentation in perimenopausal depression. Maturitas (2006) 0.79
Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. CNS Spectr (2013) 0.79
The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine. J Clin Neurophysiol (2011) 0.78
Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence. Clin EEG Neurosci (2009) 0.78
Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: An Updated Systematic Review and Meta-analysis. J ECT (2016) 0.78
Influence of age, gender, health status, and depression on quantitative EEG. Neuropsychobiology (2005) 0.77
Predictors of improved mood over time in clinical trials for major depression. Psychiatry Res (2004) 0.77
Manipulation of cigarette craving with transcranial magnetic stimulation. Biol Psychiatry (2011) 0.77
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord (2011) 0.77
Effects of heart disease on depression treatment: results from the COMED study. Gen Hosp Psychiatry (2011) 0.76
Does prior antidepressant treatment of major depression impact brain function during current treatment? Eur Neuropsychopharmacol (2012) 0.76
Pretreatment neurophysiologic function and ECT response in depression. J ECT (2004) 0.76
Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study. Pain Med (2009) 0.76
Amygdala lateralization at rest and during viewing of neutral faces in major depressive disorder using low-resolution brain electromagnetic tomography. Clin EEG Neurosci (2010) 0.76